Please check your internet connection and try again.
# Ezivac Enema
## Overview
Ezivac enema is a hypertonic saline laxative containing sodium phosphate monobasic and sodium phosphate dibasic. It acts via osmotic pressure to draw fluid into the colon, increasing volume and stimulating peristalsis. It is typically prepared as a ready-to-use disposable enema.
## Primary Indications
* Relief of occasional constipation.
* Bowel evacuation prior to proctoscopic or sigmoidoscopic examinations.
## Adult Dosing
* **Constipation:** 118 mL (one ready-to-use bottle) administered rectally as a single dose.
* **Maximum:** Do not exceed one dose in 24 hours.
## Pediatric Dosing
* **Children 2 to 11 years:** 59 mL (half of a standard 118 mL unit or a pediatric-sized unit) administered rectally as a single dose.
* **Children under 2 years:** Use is generally contraindicated due to the risk of severe electrolyte disturbances.
* **Maximum:** Do not exceed one dose in 24 hours.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Significant risk of hyperphosphatemia, hypocalcemia, and hypernatremia. Avoid in patients with pre-existing renal insufficiency.
* **Dehydration:** Avoid use in patients with pre-existing dehydration or those unable to maintain adequate oral hydration.
## Contraindications
* Hypersensitivity to sodium phosphates or any component of the product.
* Megacolon (congenital or acquired).
* Gastrointestinal obstruction or perforation.
* Active inflammatory bowel disease (e.g., ulcerative colitis).
* Congestive heart failure or clinically significant impaired renal function.
* Patients on a sodium-restricted diet.
## Adverse Effects
* **Common:** Abdominal pain, bloating, nausea, anal irritation.
* **Serious:** Severe electrolyte imbalances (hypernatremia, hyperphosphatemia, hypocalcemia, hypokalemia), metabolic acidosis, dehydration, and rarely, permanent renal damage (nephrocalcinosis).
## Key Drug Interactions
* **Diuretics:** May exacerbate electrolyte imbalances and dehydration.
* **ACE Inhibitors/ARBs/NSAIDs:** Concurrent use increases the risk of acute phosphate nephropathy and renal impairment.
* **Calcium Channel Blockers:** Potential for increased risk of hypocalcemia.
## Monitoring
* Monitor for signs of dehydration (dizziness, dry mouth, oliguria).
* In vulnerable populations, monitor serum electrolytes (phosphate, calcium, sodium, potassium) and renal function (BUN/Cr) post-administration if symptoms suggest metabolic disturbance.
## Clinical Pearls
* **Positioning:** Instruct patients to lie on the left side with knees bent (Sims' position) during administration.
* **Hydration:** Strongly encourage the patient to drink plenty of water or clear liquids before and after the enema to prevent dehydration.
* **Duration:** Should not be used for more than 7 days; if constipation persists, re-evaluate for underlying pathology.
* **Administration:** Ensure the applicator tip is lubricated; stop administration if resistance is met to avoid rectal perforation.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical protocols and prescribing information vary by region and institution. Always verify current dosage, contraindications, and patient-specific factors via official drug monographs (e.g., Lexicomp, UpToDate) or institutional pharmacy guidelines before prescribing or administering.
